sound pharmaceuticals

Sound Pharmaceuticals Advances Phase 2 Clinical Trial in Cystic Fibrosis Patients to Prevent Hearing Loss

SEATTLE, WASHINGTON AND CHARLESTON, SOUTH CAROLINA Sound Pharmaceuticals, a Seattle-based biotech firm, announced that first-patient-in has been achieved in the STOP Ototoxicity Phase 2 clinical trial. This novel interventional study with the company’s oral drug, SPI-1005, is aimed to prevent and treat ototoxicity in patients with Cystic Fibrosis undergoing intravenous (IV) tobramycin for the treatment of acute pulmonary exacerbation.

One of the most common side effects of aminoglycoside antibiotics, such as tobramycin, is ototoxicity, which can leave patients with permanent hearing loss, tinnitus or dizziness issues. Aminoglycoside antibiotics commonly used to treat respiratory infections involving gram negative bacteria (Pseudomonas).

Last year, Sound Pharmaceuticals was awarded up to $1.6M from the Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), a non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation, to support its research efforts and development of SPI-1005.


Stopping Ototoxicity


The STOP Ototoxicity study is led by Patrick Flume, MD, Professor of Medicine and Pediatrics at MUSC in Charleston, South Carolina. Dr. Flume is an international expert in CF and pulmonary disease and has co-chaired the development of the CF Foundation’s care guidelines on the treatment of pulmonary exacerbations.

“The prevalence of hearing loss and incidence of ototoxicity in this tobramycin receiving CF population underscores the critical need for an effective neurotologic treatments”

–Patrick Flume, MD

In the recently completed Phase 1b study reported at the North American CF Conference in Denver, CO, 80-100% of the CF patients showed signs of ototoxicity including clinically relevant hearing loss one month after completing one IV course of tobramycin. In addition, approximately 50% of the volunteers had moderate to moderately-severe hearing loss at baseline or the start of IV tobramycin treatment. “The significant hearing loss documented in this young adult population (average age was 27) was twice of what we expected,” said Jonathan Kil, MD, Sound Pharmaceuticals CEO and Chief Medical Officer.

Currently, there are no FDA approved therapies for the prevention or treatment of ototoxicity or any other type of sensorineural hearing loss, tinnitus, or dizziness. The company currently has four active Investigational New Drug Applications involving the inner ear or neurotology underway.


Source: Sound Pharmaceuticals